CN113769119B - 一种医用超声耦合剂及其制备方法 - Google Patents
一种医用超声耦合剂及其制备方法 Download PDFInfo
- Publication number
- CN113769119B CN113769119B CN202111205277.4A CN202111205277A CN113769119B CN 113769119 B CN113769119 B CN 113769119B CN 202111205277 A CN202111205277 A CN 202111205277A CN 113769119 B CN113769119 B CN 113769119B
- Authority
- CN
- China
- Prior art keywords
- percent
- solution
- valrocemide
- coupling agent
- uniformly stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000007822 coupling agent Substances 0.000 title abstract description 17
- RALGCAOVRLYSMA-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-2-propylpentanamide Chemical compound CCCC(CCC)C(=O)NCC(N)=O RALGCAOVRLYSMA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229950007915 valrocemide Drugs 0.000 claims abstract description 22
- 241000588724 Escherichia coli Species 0.000 claims abstract description 11
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 239000003899 bactericide agent Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 241000192125 Firmicutes Species 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 23
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract description 15
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 abstract description 12
- 241000222122 Candida albicans Species 0.000 abstract description 11
- 229940095731 candida albicans Drugs 0.000 abstract description 11
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 abstract description 9
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 abstract description 9
- 229940051841 polyoxyethylene ether Drugs 0.000 abstract description 9
- 229920000056 polyoxyethylene ether Polymers 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 239000004925 Acrylic resin Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 150000002191 fatty alcohols Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 65
- 238000003756 stirring Methods 0.000 description 48
- 238000005303 weighing Methods 0.000 description 25
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 6
- 239000004584 polyacrylic acid Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种医用超声耦合剂及其制备方法,属于医用超声耦合剂技术领域。本发明所提供的超声耦合剂包括如下制备原料:Valrocemide0.01~0.02%,十二烷基二甲基苄基氯化铵0.01~0.1%,对羟基苯甲酸酯0.1~0.8%,棕榈酸异丙酯1.0~3.0%,脂肪醇聚氧乙烯醚0.1‑0.5%,交联聚丙烯酸树脂0.1~0.6%,丙三醇5.0~10.0%,三乙醇胺0.1~0.5%,其余为水。本发明发现Valrocemide抑制大肠杆菌,金黄色葡萄球菌和白色念珠菌的新功能,并利用其制备了一种新型的医用超声耦合剂,本发明所制备医用超声耦合剂的可以实现广谱杀菌和高效杀菌,并实现整个超声诊疗过程中对超声探头进行杀菌消毒,有效降低超声检测过程中交叉感染风险。
Description
技术领域
本发明属于医用超声耦合剂技术领域,尤其提供了一种医用超声耦合剂及其制备方法。
背景技术
随着临床超声诊断的广泛应用,医用超声探头因频繁接触不同患者导致携带多种致病微生物,存在医源性交叉感染的潜在危险,目前临床上主要采用薄膜隔离法或采用保鲜袋包裹探头、化学消毒法包括用75%乙醇擦拭探头或紫外线照射消毒法等方法预防和阻断超声探头的交叉污染。由于这些消毒方法操作繁琐、易损伤探头、消毒时间长,所以依从性较差。超声探头价格昂贵,检测频繁,每个患者都换一个新超声探头是不现实的;而且,超声探头材质及使用要求的特殊性,不能采用对塑料和橡胶具有腐蚀性和溶胀性的消毒剂,也不能使用常规的浸泡、高温高压等方法进行消毒。
因此,研究开发新的医用超声耦合剂具有非常重要的意义,Valrocemide是一种有前景的抗癫痫候选分子抑制剂,但是目前关于Valrocemide在杀菌方面的研究尚未见报道。
发明内容
本发明的目的在于提供一种新的医用超声耦合剂及其制备方法,同时,本发明的目的在于提供一种Valrocemide的新用途。
为实现上述目的,本发明提供了如下技术方案:
本发明提供了一种医用消毒杀菌超声耦合剂,所述超声耦合剂包括如下制备原料:Valrocemide0.01~0.02%,十二烷基二甲基苄基氯化铵 0.01~0.1%,对羟基苯甲酸酯0.1~0.8%,棕榈酸异丙酯 1.0~3.0%,脂肪醇聚氧乙烯醚0.1-0.5%,交联聚丙烯酸树脂0.1~0.6%,丙三醇5.0~10.0%,三乙醇胺0.1~0.5%,其余为水。
优选地,所述Valrocemide的分子式为C10H20N2O2。
优选地,所述超声耦合剂的制备方法包括如下步骤:
(1)称取十二烷基二甲基苄基氯化铵加入纯化水中,充分搅拌均匀,得到溶液A;
(2)称取Valrocemide、对羟基苯甲酸酯、棕榈酸异丙酯、脂肪醇聚氧乙烯醚和丙三醇,充分搅拌均匀,得到溶液B;
(3)将所述溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将所述溶液C缓慢加入到所述溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取三乙醇胺,缓慢加入到所述溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂。
其次,本发明提供了一种医用消毒杀菌超声耦合剂的制备方法,其特征在于,每100g医药超声耦合剂的制备方法包括如下步骤:
(1)称取0.01~0.1g十二烷基二甲基苄基氯化铵加入纯化水中,充分搅拌均匀,得到溶液A;
(2)称取0.01~0.02g Valrocemide、0.1~0.8g对羟基苯甲酸酯、1.0~3.0g棕榈酸异丙酯、0.1-0.5g脂肪醇聚氧乙烯醚和5.0~10.0g丙三醇,充分搅拌均匀,得到溶液B;
(3)将所述溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取0.1~0.6g交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将所述溶液C缓慢加入到所述溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取0.1~0.5g三乙醇胺,缓慢加入到所述溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂。
其次,本发明提供了Valrocemide在制备杀菌剂中的用途,所述Valrocemide的分子式为C10H20N2O2。
优选地,所述杀菌剂为革兰氏阳性菌杀菌剂,革兰氏阴性菌杀菌剂,或真菌杀菌剂。
优选地,所述革兰氏阳性菌为金黄色葡萄球菌,所述革兰氏阴性菌为大肠杆菌,所述真菌为白色念球菌。
优选地,所述革兰氏阳性菌杀菌剂的最小使用剂量为1.25ug/ml,所述革兰氏阴性菌杀菌剂的最小使用剂量为2.5ug/ml,所述真菌杀菌剂的最小使用剂量为1.25ug/ml。
最后,本发明提供了Valrocemide在制备医用消毒杀菌超声耦合剂中的应用,其特征在于,所述超声耦合剂包括如下制备原料:Valrocemide0.01~0.02%,十二烷基二甲基苄基氯化铵0.01~0.1%,对羟基苯甲酸酯0.1~0.8%,棕榈酸异丙酯 1.0~3.0%,脂肪醇聚氧乙烯醚0.1-0.5%,交联聚丙烯酸树脂0.1~0.6%,丙三醇5.0~10.0%,三乙醇胺0.1~0.5%,其余为水;
所述超声耦合剂的制备方法包括如下步骤:
(1)称取十二烷基二甲基苄基氯化铵加入纯化水中,充分搅拌均匀,得到溶液A;
(2)称取Valrocemide、对羟基苯甲酸酯、棕榈酸异丙酯、脂肪醇聚氧乙烯醚和丙三醇,充分搅拌均匀,得到溶液B;
(3)将所述溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将所述溶液C缓慢加入到所述溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取三乙醇胺,缓慢加入到所述溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂。
优选地,所述Valrocemide的分子式为C10H20N2O2。
本发明的有益效果是:
本发明发现Valrocemide抑制大肠杆菌,金黄色葡萄球菌和白色念珠菌的新功能,并利用其制备了一种新型的医用超声耦合剂,本发明所制备的可以实现广谱杀菌和高效杀菌,并实现整个超声诊疗过程中对超声探头进行杀菌消毒,有效降低超声检测过程中交叉感染风险。
具体实施方式
为能清楚说明本方案的技术特点,下面通过具体实施方式,对本方案进行阐述。
实施例1
(1)称取0.01g 十二烷基二甲基苄基氯化铵加入5g纯化水中,充分搅拌均匀,得到溶液A;
(2)称取0.02g Valrocemide、0.8g对羟基苯甲酸酯、3.0g棕榈酸异丙酯、0.5g脂肪醇聚氧乙烯醚和10.0g丙三醇,充分搅拌均匀,得到溶液B;
(3)将溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取0.6g交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将溶液C缓慢加入到溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取0.5g三乙醇胺,缓慢加入到溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂A。
实施例2
(1)称取0.05g十二烷基二甲基苄基氯化铵加入5g纯化水中,充分搅拌均匀,得到溶液A;
(2)称取0.02g Valrocemide、0.4g对羟基苯甲酸酯、2.0g棕榈酸异丙酯、0.3g脂肪醇聚氧乙烯醚和8.0g丙三醇,充分搅拌均匀,得到溶液B;
(3)将溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取0.4g交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将溶液C缓慢加入到溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取0.4g三乙醇胺,缓慢加入到所述溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂B。
实施例3
(1)称取0.1g十二烷基二甲基苄基氯化铵加入5g纯化水中,充分搅拌均匀,得到溶液A;
(2)称取0.01gValrocemide、0.1g对羟基苯甲酸酯、1.0g棕榈酸异丙酯、0.1g脂肪醇聚氧乙烯醚和5.0g丙三醇,充分搅拌均匀,得到溶液B;
(3)将溶液A在搅拌状态下缓慢加入到溶液B中,充分搅拌均匀,得到溶液C;
(4)称取0.1g交联聚丙烯酸树酯分散到纯化水中,充分搅拌均匀,得到溶液D;
(5)将溶液C缓慢加入到溶液D中,快速搅拌均匀后,补足水分,继续搅拌均匀,得到溶液E;
(6)称取0.1g三乙醇胺,缓慢加入到所述溶液E中,调节PH为7,充分搅拌均匀后,得到超声耦合剂B。
实施例4
不同浓度的Valrocemide的抑菌圈大小
(1)称取6g素琼脂于300ml蒸馏水加热溶解,分装于3个250ml三角瓶中高压灭菌;
(2)冷却至50℃左右时,在超净工作台上倒入无菌培养皿中,每个培养皿约5ml,水平放置,让其均匀铺满培养皿底部;
(3)凝固后在平板上均匀放置4个无菌牛津杯(内径为6mm,外径为8mm)备用;
(4)去营养琼脂33g于1L水中加热至完全溶解,分装于250ml的三角瓶中灭菌,待培养基冷却至50℃左右时,取2ml金黄色葡萄球菌,大肠杆菌菌液和白色念珠菌于100ml培养基中摇匀;
(5)趁热将没凝固的含菌营养琼脂培养基倒入摆放了牛津杯的素琼脂平板上层,每个平板约10ml,水平放置均匀铺满平板;
(6)待凝固后取下牛津杯,向含有不同测试菌平板的牛津孔中分别加入80ul的1ug/ml,5ug/ml和10ug/ml的Valrocemide溶液,同时,使用无菌生理盐水作为对照;
(7)将金黄色葡萄球菌和大肠杆菌平板置于37℃放置24h,白色念珠菌平板置于37℃放置48h,测定抑菌圈大小。
表1 不同浓度Valrocemide的抑菌圈大小
1ug/ml | 5ug/ml | 10ug/ml | |
金黄色葡萄球菌 | 9.38±0.19 | 13.47±0.38 | 16.24±0.31 |
大肠杆菌 | 8.17±0.18 | 10.75±0.49 | 14.02±0.22 |
白色念珠菌 | 10.69±0.34 | 16.40±0.19 | 19.05±0.37 |
从表1中可以看出,Valrocemide对于金黄色葡萄球菌,大肠杆菌,白色念珠菌均具有较好的抑制效果,其中,对于白色念珠菌的抑制效果最佳。
实施例5
测定Valrocemide的最低抑菌浓度(MIC)
(1)使用二倍稀释法将Valrocemide溶液稀释成浓度50、25、12.5、6.25、3.125ug/ml的梯度溶液;
(2)灭菌后分别去1ml加入到9ml含有大肠杆菌,金黄色葡萄球菌、白色念珠菌的融化营养琼脂中混匀,使其浓度为5、2.5、1.25、0.625、和0.3125ug/ml;
(3)倒平板后,在37℃培养24h,观察菌体的生长情况,以确定作为最低抑菌浓度。
表2 Valrocemide的最低抑菌浓度
5 ug/ml | 2.5 ug/ml | 1.25 ug/ml | 0.625ug/ml | 0.3125 ug/ml | |
金黄色葡萄球菌 | - | - | - | ++ | ++ |
大肠杆菌 | - | - | + | ++ | ++ |
白色念珠菌 | - | - | - | + | ++ |
在表2中“-”代表无菌生长,“+”代表少量菌生长,“++”代表大量菌生长。
从表2中,可知,Valrocemide对于金黄色葡萄球菌的MIC为1.25ug/ml,对于大肠杆菌的MIC为2.5ug/ml,对于白色念珠菌的MIC为1.25ug/ml。
实施例6
对本发明实施例2所制备的超声耦合剂进行抽样检测,按《消毒技术规范》(2002年版)和YY0299-2016 医用超声耦合剂的要求进行测定,测定结果如下:
通过上述结果可以看出,本发明所提供的超声耦合剂的产品性能符合要求,且具有优异的效果。
本发明未经描述的技术特征可以通过或采用现有技术实现,在此不再赘述,当然,上述说明并非是对本发明的限制,本发明也并不仅限于上述举例,本技术领域的普通技术人员在本发明的实质范围内所做出的变化、改型、添加或替换,也应属于本发明的保护范围。
Claims (1)
1. Valrocemide在制备革兰氏阳性菌杀菌剂和革兰氏阴性菌杀菌剂中的用途,其特征在于,所述Valrocemide的分子式为C10H20N2O2;
所述革兰氏阳性菌为金黄色葡萄球菌,所述革兰氏阴性菌为大肠杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111205277.4A CN113769119B (zh) | 2021-10-15 | 2021-10-15 | 一种医用超声耦合剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111205277.4A CN113769119B (zh) | 2021-10-15 | 2021-10-15 | 一种医用超声耦合剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113769119A CN113769119A (zh) | 2021-12-10 |
CN113769119B true CN113769119B (zh) | 2022-12-09 |
Family
ID=78873201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111205277.4A Active CN113769119B (zh) | 2021-10-15 | 2021-10-15 | 一种医用超声耦合剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113769119B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2415487B1 (en) * | 2010-08-02 | 2014-10-08 | angioclinic AG | An ultrasonic couplant composition |
EP3222324B1 (en) * | 2016-03-23 | 2020-05-13 | Wayne State University | Valproate as a topical anti-fungal treatment |
CN109675069A (zh) * | 2019-02-26 | 2019-04-26 | 山东科宏医疗科技有限公司 | 一种医用消毒超声耦合剂及其制备方法 |
-
2021
- 2021-10-15 CN CN202111205277.4A patent/CN113769119B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113769119A (zh) | 2021-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1816330B (zh) | 抗菌组合物,方法和系统 | |
CN111096322A (zh) | 一种适于低温使用的戊二醛癸甲溴铵复合消毒剂 | |
Shubha et al. | Evaluation of antimicrobial activity of Rasaka Bhasma | |
RU2455355C1 (ru) | ШТАММ БАКТЕРИОФАГА Pseudomonas aeruginosa, ИСПОЛЬЗУЕМЫЙ В КАЧЕСТВЕ ОСНОВЫ ДЛЯ ПРИГОТОВЛЕНИЯ АСЕПТИЧЕСКОГО СРЕДСТВА ПРОТИВ СИНЕГНОЙНОЙ ПАЛОЧКИ | |
KR20170007312A (ko) | 미생물 성장 매체 및 이를 이용하는 방법 | |
CN113769119B (zh) | 一种医用超声耦合剂及其制备方法 | |
CN111066781A (zh) | 一种适于低温使用的灭威林消毒剂 | |
Morton et al. | The bacteriostatic and bactericidal actions of some mercurial compounds on hemolytic streptococci: in vivo and in vitro studies | |
CN102178963B (zh) | 医用超声耦合剂及其制备方法 | |
CN110585450A (zh) | 医用消毒杀菌型超声耦合剂 | |
CN104667267A (zh) | 一种皮肤外用溶菌酶复合制剂及制造方法 | |
Lawrence et al. | Iodophors as disinfectants | |
CN114159337B (zh) | 一种含重组人溶菌酶的面部抗菌护理液 | |
JP3590019B2 (ja) | カビ付着防止剤及び脱臭剤、並びにそれを用いたカビ付着防止方法及び脱臭方法 | |
CN105638773A (zh) | 一种用于手术室器械消毒的多元纳米喷雾剂及其制备方法 | |
CN114209646A (zh) | 一种聚维酮碘温敏凝胶制剂 | |
JPS59102399A (ja) | 試料の微生物的状熊の保持方法 | |
CN109221102A (zh) | 一种抑菌新材料 | |
CN112341664B (zh) | 一种活性剂、无氧玻尿酸生产方法及其制品 | |
CN104304237A (zh) | 一种安全高效的动物精液消毒剂及其制备方法 | |
CN101773516B (zh) | 一种阴道用酸性缓冲凝胶制剂及其制备方法和应用 | |
CN108486211A (zh) | 幽门螺杆菌药敏检测培养基及试剂盒 | |
CN114028589A (zh) | 一种复合溶菌酶杀菌消毒型超声耦合剂及其制备方法 | |
Frobisher Jr et al. | A study of the effect of alcohols on tubercle bacilli and other bacteria in sputum | |
CN106659164A (zh) | 用于保护皮肤的包含五水合铜盐和七水合锌盐的杀菌制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Danhong Inventor after: Wang Shihao Inventor after: Qin Luming Inventor after: Lin Lili Inventor before: Yang Danhong Inventor before: Wang Shihao Inventor before: Qin Luyue Inventor before: Lin Lili |
|
CB03 | Change of inventor or designer information |